Teriparatide oral - Bone Medical

Drug Profile

Teriparatide oral - Bone Medical

Alternative Names: BN-003; CaPTHymone; Perthoxal™; PTH - Bone Medical

Latest Information Update: 26 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bone Medical
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Osteoporosis

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 28 Jan 2013 Phase-II clinical trials in Osteoporosis in Australia (PO)
  • 12 May 2008 Pharmacodynamics data from a phase I/II trial in Osteoporosis released by Bone Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top